E
VistaGen Therapeutics, Inc. VTGN
$1.97 -$0.08-3.90% NASDAQ
Recommendation
Prev Close
$1.97
Volume
222,355
Avg Vol (90D)
147,270
Market Cap
$57.44M
Dividend & Yield
--
52-Week Range
$1.90 - $4.21
P/E (TTM)
--
EPS (TTM)
-$1.66
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
15 Best Growth Stocks to Buy for the Next 5 Years
6/26/2025 - Insider Monkey
Vistagen Appoints Elissa Cote as Chief Development Officer
6/25/2025 - TipRanks Financial Blog
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
6/25/2025 - Business Wire
William Blair Issues Negative Forecast for VTGN Earnings
6/23/2025 - MarketBeat
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript
6/22/2025 - Insider Monkey
Vistagen Therapeutics' Earnings Call Highlights Progress and Challenges
6/20/2025 - TipRanks Financial Blog
What is William Blair's Forecast for VTGN Q1 Earnings?
6/19/2025 - MarketBeat
We're Keeping An Eye On Vistagen Therapeutics' (NASDAQ:VTGN) Cash Burn Rate
6/19/2025 - Simply Wall St
Stifel Nicolaus Sticks to Its Buy Rating for VistaGen Therapeutics (VTGN)
6/19/2025 - TipRanks Financial Blog
VistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William Blair
6/19/2025 - MarketBeat
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...
6/18/2025 - GuruFocus
Q4 2025 Vistagen Therapeutics Inc Earnings Call Transcript
6/18/2025 - GuruFocus
Vistagen Therapeutics Reports Progress in Clinical Trials
6/18/2025 - TipRanks Financial Blog
Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript
6/17/2025 - SeekingAlpha
Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript
6/17/2025 - Seeking Alpha: Transcripts
Vistagen Therapeutics Inc Reports Q1 Revenue of $0.49M, Surpassing Estimates; EPS at -$1.67
6/17/2025 - GuruFocus
Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS
6/17/2025 - MarketBeat
VistaGen Files Prospectus to Raise $175 Million
6/17/2025 - TipRanks Financial Blog
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
6/17/2025 - Business Wire
Insights into VistaGen Therapeutics's Upcoming Earnings
6/16/2025 - Benzinga
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For
6/16/2025 - GuruFocus
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
6/12/2025 - Business Wire
Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday
6/3/2025 - MarketBeat
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
6/2/2025 - Business Wire
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
5/28/2025 - Business Wire
Income Statement
Total Revenue (TTM)
$486.00K
EBITDA (TTM)
-$55.82M
EBIT (TTM)
-$55.97M
Net Income (TTM)
-$51.42M
Balance Sheet
Total Assets (Q)
$84.34M
Total Debt (Q)
$1.51M
Total Liabilities (Q)
$13.95M
Book Value Per Share (Q)
$2.43
Cash Flow
Cash from Operations (TTM)
-$42.10M
Cash from Investing (TTM)
-$13.15M
Cash from Financing (TTM)
$3.21M
Net Change in Cash (TTM)
-$52.04M
Filings
Filing Date
Tuesday, June 17, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
0.67
7-Day Total Return
-4.37%
30-Day Total Return
-14.35%
60-Day Total Return
-17.57%
90-Day Total Return
-30.88%
Year to Date Total Return
-40.57%
1-Year Total Return
-43.39%
2-Year Total Return
14.53%
3-Year Total Return
-92.78%
5-Year Total Return
-87.73%
52-week Low
Apr 09, 2025 - $1.90
52-week High
Jul 11, 2024 - $4.21
Valuation
Market Cap
$57.44M - Micro Cap
Enterprise Value
-$21.53M
Price/Sales (TTM)
128.76
Price/Book (Q)
0.81
Dividends and Shares
Shares Outstanding
31.56M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.vistagen.com
Phone Number
650 577 3600
Address
343 Allerton Avenue
South San Francisco, CA 94080
Country
United States
Year Founded
1998
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The... more
NASDAQ 06/27/2025 4:00PM Eastern Quotes delayed